| bibliographicCitation |
Rha SY, Oh D, Yañez P, Bai Y, Ryu M, Lee J, Rivera F, Alves GV, Garrido M, Shiu K, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS, Mendez G, O'Connor JM, Yanzi Castilla A, Cundom J, Kaen D, Wong R, Ng W, Aghmesheh M, Peressoni M, Andrade C, Franke F, Alves G, Cruz FJ, Vianna K, Monteiro MM, Raphael M, Berry S, Jang R, Tan A, Asselah J, Yanez Weber P, Mahave M, Sanchez C, Salman P, Bai Y, Li J, Zhang X, Liu T, Lin X, Qin S, Yang J, Luo S, Li W, Ying J, Chen X, Zeng S, Qu Y, Yang L, Zhao L, Chen P, Pan H, Li E, Ye F, Lu J, Liang X, Zhao Q, Yin X, Li J, Ling Y, Lv G, Li S, Guerrero A, Rubiano J, Gonzalez Fernandez M, Manneh Kopp R, Guzman Ramirez A, Corrales L, Gonzalez Herrera I, Melichar B, Buchler T, Svoboda T, Obermannova R, Vrana D, Cvek J, Pfeiffer P, Baeksgaard L, Yilmaz M, Boige V, Lopez-Trabada D, Borg C, Pannier D, Hiret S, Di Fiore F, Metges J, Arnold D, Martens U, Lordick F, Stein A, Castro H, Lopez K, Ramirez J, Aguilar M, Chivalan M, Chan W, Cheng A, Yeo W, Arkosy P, Csoszi T, Hitre E, Horvath Z, Lowery M, McDermott R, Morris P, Hubert A, Brenner B, Ben-Aharon I, Shacham-Shmueli E, Man S, Pelles Avraham S, Brenner R, Mishaeli M, Di Bartolomeo M, Fazio N, Lonardi S, Garufi C, Satoh T, Hara H, Iwagami S, Yasui H, Tsuda M, Shimoyama T, Shoji H, Sugimoto N, Shibata N, Yamaguchi K, Amagai K, Choda Y, Esaki T, Yabusaki H, Oshima T, Tsuji A, Kawakami H, Kawazoe A, Ishido K, Kadowaki S, Martinez Rodriguez J, Herrera Martinez M, Huitzil Melendez F, Ramirez Godinez F, Balancan P, Damianovich D, Castro Oliden V, Grados J, Torres C, Wyrwicz L, Wysocki P, Hajac L, Zolnierek J, Karaszewska B, Rha SY, Lee J, Ryu M, Oh D, Orlova R, Tjulandin S, Fadeeva N, Makarycheva Y, Nosov D, Smagina M, Chan S, Jacobs C, Kraus P, Landers G, Robertson B, Ruff P, Schoeman E, Maurel J, Diez Garcia M, Jimenez Fonseca P, Gallego Plazas J, Rivera Herrero F, Miranda Poma J, Layos Romero L, Fritsch R, Bastian S, Winterhalder R, Dosso SD, Kossler T, Yeh K, Yen C, Chen Y, Lin J, Bilici M, Ozguroglu M, Cil T, Oksuzoglu B, Harputluoglu H, Karaoglu A, Hacibekiroglu I, Erdogan B, Yalcin S, Adamchuk H, Bondarenko I, Kolesnik O, Ostapenko Y, Kryzhanivska A, Leshchenko L, Ilin I, Shparyk Y, Trukhin D, Voitko N, Roy R, Young A, Medley L, Shiu K, Celano P, Overton L, Raj M, Dunne R, Wainberg Z, Dayyani F, Larson T, Kochenderfer M. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. The Lancet Oncology. 2023 Nov;24(11):1181–95. doi: 10.1016/s1470-2045(23)00515-6. |